Work

Novel Small Molecule Inhibitors of GSL-1 as Potential Agents for the Treatment of Metabolic Disorders

Year: 2026
Type: article
Abstract: Small molecule inhibitors of glutaminase (GSL1) are described as potential treatment of metabolic diseases including obesity, diabetes, liver diseases, muscular atrophy and atherosclerosis. Glutaminolysis is an alternative to glycosis as a source of carbon for energy homeostasis and is a major source of energy in the brain and other organs. Glutaminase (GSL1) is a mitochondrial enzyme converting glutamine into glutamate through glutaminolysis. Excessive glutaminolysis is associated with accelerated aging.
Author: Gerard Rosse
Language: English
Subfield: Biochemistry
Open Access status: bronze
OpenAlex ID: W7228632357
FWCI:
Cites: 1
Cited by:
Related to: 10